SLC6A7: A Potential Drug Target and Biomarker for Many Diseases

Target Name: SLC6A7

NCBI ID: G6534

SLC6A7

SLC6A7: A Potential Drug Target and Biomarker for Many Diseases

SLC6A7 (Protoproteinase 6A7) is a protein that is expressed in a wide range of tissues throughout the body. It is a member of the P2A family of proteins, which are involved in a variety of cellular processes, including cell signaling, DNA replication, and protein degradation. SLC6A7 has also been shown to play a role in the regulation of cell adhesion, and is expressed in tissues that are involved in cell-cell and cell-tissue interactions, such as the placenta, muscle, and liver.

One of the unique features of SLC6A7 is its ability to generate a highly specific antibody response in response to a variety of different antigens. This is achieved through its use of the N-terminal extracellular domain (N-ED), which is known as a nucleotide-binding oligomerization (NBO) domain. This domain is able to bind to specific nucleotides in the target RNA, allowing SLC6A7 to generate a highly specific antibody response to a wide range of different antigens.

SLC6A7 has also been shown to play a role in the regulation of cell signaling pathways. For example, studies have shown that SLC6A7 can interact with the protein tyrosine kinase TPK2, and that this interaction is involved in the regulation of TPK2 activity. This suggests that SLC6A7 may be a potential drug target for the treatment of tyrosine kinase-related diseases.

In addition to its potential role as a drug target, SLC6A7 has also been shown to be a valuable biomarker for a variety of different diseases. For example, studies have shown that SLC6A7 is expressed in a variety of different tissues and that it is involved in the regulation of cell adhesion, which is a critical process involved in the development and progression of many diseases. Additionally, SLC6A7 has been shown to be involved in the regulation of cell signaling pathways, which is involved in the development and progression of many other diseases.

Overall, SLC6A7 is a protein that has the potential to be a valuable drug target or biomarker for a wide range of different diseases. Further research is needed to fully understand its role in cellular processes and to develop effective treatments.

Protein Name: Solute Carrier Family 6 Member 7

Functions: Brain specific sodium (and chloride)-dependent proline transporter (PubMed:7651355). Terminates the action of proline by its high affinity sodium-dependent reuptake into presynaptic terminals (Probable)

The "SLC6A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets